Results: 350 patients enrolled (75% women; mean age 5913.6 years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n=304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least "Much improved" was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n=6), muscle weakness (n=4), and neck pain (n=3).
INTRODUCTION
Cervical dystonia (CD) is a chronic movement disorder characterized by abnormal posturing or involuntary movements of the neck, head, and shoulders [1, 2] . The movements observed in CD are often complex and can include rotation (rotocollis), flexion (anterocollis), extension (retrocollis), or tilting (laterocollis) [2, 3] . In clinical practice, CD is heterogeneous in its presentation, with a wide range of symptom severity and patient comorbidities [3] . The disorder can have a major impact on patient quality of life [2, 4] .
CD is the most common adult-onset focal dystonia, with an estimated prevalence of 28-183 cases per million people in the general population [3] . Geographical and ethnic differences may play a role in the wide range of prevalence estimates. For example, in a study of the multiethnic membership of a health maintenance organization in Northern California, prevalence of CD was higher in white patients of European descent than among Hispanic, Asian, or AfricanAmerican patients [5] .
Botulinum neurotoxin type A (BoNT-A) is established as an effective treatment for CD [6, 7] . This neurotoxin inhibits the release of acetylcholine from the presynaptic neuron, inducing a graded muscle weakness. As a result of weakening dystonic muscles, there is a reduction in symptoms with improvement in pain and in control over voluntary head and neck movements.
Relief is transient, and the effect wears off over the course of months [8, 9] .
AbobotulinumtoxinA (Dysport ® , Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is a BoNT-A indicated for the treatment of adults with CD [10] . The efficacy and safety of abobotulinumtoxinA for CD has been established in 2 randomized, controlled clinical trials and their open-label safety extensions [10] [11] [12] . Controlled studies, however, may not accurately reflect "real life" outcomes. Prospective naturalistic studies are needed to assess the effectiveness
of treatment in routine daily practice, particularly in view of the heterogeneity of CD and the diversity in injection techniques by physicians across a variety of clinical practices.
ANCHOR-CD was a prospective, open-label, observational registry designed to evaluate the efficacy and safety of abobotulinumtoxinA for a 1-year period of repeated injections in adults with idiopathic CD treated in routine clinical practice in the United States.
METHODS

1 Study Population
Adult patients diagnosed with isolated (idiopathic) CD who gave their informed consent to participate were eligible for enrollment in the study. Patients could be BoNT-naïve or previously treated with BoNT if at least 12 weeks had elapsed since the last BoNT-A or BoNT-B injection. Patients were ineligible to participate if they had secondary CD, if they anticipated concomitant treatment with BoNT for indications other than CD, or if based on investigator opinion, previous BoNT-A or BoNT-B therapy had produced an insufficient response or intolerable adverse event (AE). The decision to prescribe abobotulinumtoxinA was to be made before and independently from the decision to enroll the patient in the registry. This study obtained appropriate institutional review board approval and was conducted under the provisions of the Declaration of Helsinki.
Treatment and Assessments
AbobotulinumtoxinA was administered by intramuscular injection over 4 treatment cycles. The muscles selected for injection, the number of injections into each muscle, doses of
BoNT, and method of administration were determined by the investigators in accordance with their standard of practice.
The recommended treatment cycle intervals in the study were consistent with the United States labeling for Dysport® (ie, every 12 weeks). The treating physician determined the dose and treatment interval, taking into account patient response and label recommendations. For the first injection (Cycle 1), in-office physician assessments were made at baseline and Week 4 following the injection. These assessments included the TWSTRS total and subscale scores (severity, disability, and pain). The TWSTRS Total score (maximum score of 85) was derived from the sum of the TWSTRS Severity score (0-35), the TWSTRS Disability score (0-30), and the TWSTRS Pain score (0-20). For the first cycle, CGIC was assessed at Week 4 using a 7-point Likert scale, ranging from +3 (very much improved) to -3 (very much worse). Because ANCHOR-CD was designed as a registry intended to capture data in a real-world, pragmatic setting, patients were not asked to come in to the office for physician assessments of efficacy after injection during Cycles 2 through 4. As a result, TWSTRS and CGIC data were only collected for Cycle 1.
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Patient assessments of efficacy that were collected through all four cycles of treatment included PGIC, time to waning effect of treatment, PNRS, and the modified TSQM. PGIC was assessed using the same 7-point Likert scale for CGIC ranging from +3 ("very much improved") to -3 ("very much worse"). PGIC was assessed in the office at Week 4 of Cycle 1, during each subsequent treatment visit during Cycles 2 through 4, and at the study termination visit (no sooner than 12 weeks after the fourth treatment). PGIC was also assessed by phone interviews at Satisfaction with treatment was assessed using the modified TSQM, an instrument with 6 questions assessing global satisfaction and effectiveness. Each question is rated on a 7-point scale ranging from "Extremely Satisfied" to "Extremely Dissatisfied". The modified TQSM was administered in-office at Week 4 of Cycle 1 and at the treatment visit for Cycles 2 through 4. It was also administered by phone at Week 4 of Cycles 2 through 4, and at the study termination visit.
The CDIP-58 is a validated 58-item patient-reported questionnaire assessing eight domains: head and neck symptoms, pain and discomfort, upper limb activities, walking, sleep, annoyance, mood, and psychosocial functioning. CDIP-58 was assessed at baseline, at the Cycle
Investigators were asked to report adverse drug reactions (ADRs, AEs thought to have a causative relationship to the drug) directly to the safety department of the study sponsor. AEs were reported to the study sponsor according to the regulations governing postmarketing reporting of spontaneous cases. In this paper, we include all ADRs and AEs reported to the sponsor from April 27, 2011, through April 22, 2014.
Statistical Reporting
This was an observational study and thus did not include statistical significance testing.
The response rate was calculated as the number of responders divided by the number of patients who completed TWSTRS and PGIC assessments at Week 4 of Cycle 1. An exact 95% confidence interval (CI) was calculated using the binomial distribution without a continuity correction. The 95% CIs of mean change were calculated using the normal approximation to the distribution of the sample mean. Demographic and efficacy data collected as continuo us measures were summarized by mean, SD, median, 25 th percentile, 75 th percentile, minimum, and maximum.
RESULTS
Patient Disposition and Baseline Characteristics
A total of 350 patients from 41 sites in the United States were enrolled in the study. Seventy-five percent were women. The mean age at enrollment was 59.0 ± 13.6 years, with a mean age at diagnosis of 52.9 ± 14.1 years. Most patients (67.2%) had a mixed-type CD with 25.6% having had pure torticollis (Table 1) . Most patients had received previous BoNT treatment for CD (72.6%). The most common reason for switching to abobotulinumtoxinA was efficacy (82/347, 57.3%). The second most common cause for switching was cost/reimbursement (31/347, 21.7%).
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A C C E P T E D M A N U S C R I P T Other common reasons for discontinuation included lost to follow-up and investigator decision.
Treatment Exposure
For the full study population, median dose of abobotulinumtoxinA injected, the total volume injected, and the total number of muscles injected remained relatively constant across treatment cycles. For Cycle 1, the cycle used for the primary efficacy analysis, the median dose (range) administered was 500 U (100-1500 U) and the median number of muscles injected was 4
(1-7). The splenius capitis was the most commonly injected muscle, followed by the levator scapulae and trapezius (Table 2 ).
Primary Efficacy Endpoint
Patient response rate: The response rate for the full study population who completed both TWSTRS and PGIC assessments at Week 4 (n=304) was 30.6% (95% CI, 25.5-36.1), n=93.
( Table 2 ). 
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Secondary Efficacy Endpoints
TWSTRS:
The TWSTRS Total score decreased 27.4% (SD=28.9) during Cycle 1 (n=304), with improvements noted in the Severity, Disability, and Pain TWSTRS subscale scores (Figure 2 ), indicating overall improvements in these domains. The mean percent reduction in TWSTRS Total score was comparable for BoNT-naïve (25.6%, SD 31.5), and previously treated with BoNT (27.9%, SD 28.1) patients.
PGIC:
"Much improved" or "very much improved" PGIC was rated by 43.6% of the patients at Week 4 of Cycle 1 and was maintained in injection cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively ( Figure 2 ). Similar improvements in PGIC (42.5% and 44.1%) were observed for BoNT-naïve patients and patients previously treated with BoNT.
CGIC: At Cycle 1, Week 4, approximately two-thirds (n=192) of patients with responses
(n=316) were assessed by their physician as "very much improved" (n=41) or "much improved"
(n=151) relative to baseline. Additionally, 4.6% and 4.9% of patients had "no change" or worsening symptoms, respectively (See Supplementary Table 1) .
Other secondary endpoints:
The Global Satisfaction domain score of the modified TSQM increased from 48.7% at Cycle 1, Week 4, to 57.3% at Cycle 4, Week 4, indicating an overall increase in satisfaction with treatment as patients progressed through the four treatment cycles.
Patients also reported improvements in the PNRS and all domains of the CDIP-58 (See Supplementary Table 2 .)
Safety Data
Seventeen patients (5%) experienced a total of 39 AEs, of which 11 (n=5 patients) were serious AEs. The most common AEs were dysphagia (n=6, 1.7%), muscular weakness (n=4, 1.2%), neck pain (n=3, 0.9%), and rhinorrhea (n=2, 0.6%). Three patients withdrew as a result of AEs, 2 with dysphagia and 1 with blurred vision and chewing difficulty.
Of the 39 AEs, 31 (n=13 patients) were thought to be related to the study drug (ADRs).
Of the 11 serious AEs, 6 were serious ADRs (n=3; asthenia, dysphagia, diplopia, dizziness, fall, joint injury). One patient died of an unknown cause 2 days after study completion. The death was deemed not related to study drug by the investigator. Full safety data for the registry are presented in Supplementary Table 3 .
DISCUSSION
ANCHOR-CD was a prospective, observational registry study designed to evaluate the response to abobotulinumtoxinA treatment for idiopathic CD in routine clinical practice in the United States. The results of this study support the clinical utility of abobotulinumtoxinA for managing CD-associated pain and disability in a real-world setting.
In the registry, the percentage of responders and the TWSTRS total and subscale scores were similar between BoNT-naïve and previously treated subgroups. These results suggest that BoNT-naïve patients and patients previously treated with BoNTs may have a similar response to abobotulinumtoxinA treatment.
In terms of safety, abobotulinumtoxinA was generally well-tolerated by patients in the registry. The most common AEs that were reported were dysphagia, muscular weakness, neck
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A C C E P T E D M A N U S C R I P T 13 pain, and rhinorrhea, which appear to be consistent with the known profile in the product labeling [10] .
The results from the registry were consistent with the results from two pivotal randomized, double-blind, placebo-controlled trials of abobotulinumtoxinA for the treatment of CD [11, 12] . For example, the percent decrease in TWSTRS Total score from baseline to Week 4 of the first cycle was similar across all 3 trials: 27.4%, 22.0%, and 35.6% in the ANCHOR-CD, Truong 2005, and Truong 2010, respectively[11, 12] .
Registry studies for two other BoNT-A products have also been performed. CD-PROBE was a prospective, observational study of onabotulinumtoxinA for CD (1046 patients) [13, 14] , and XCiDaBLE was a prospective observational study of incobotulinumtoxinA for blepharospasm and CD (145 patients) [15] . All three registry studies had comparable patient populations and similar patterns of muscles injected, although a higher percentage of patients in the CD-PROBE registry were BoNT-naive [14, 15] . See Supplementary Table 4 for additional details.
Although the three registries differed in terms of the timing and type of assessments performed, patients in ANCHOR-CD and CD-PROBE achieved similar reductions in TWSTRS Total score and subscale scores (TWSTRS was not assessed for XCiDaBLE). For example, 4
weeks after the first treatment in ANCHOR-CD (Cycle 1, Week 4), the TWSTRS Total score was reduced by 27.4%. Jankovic 2015 did not report on the TWSTRS results in CD-PROBE after the first treatment, but 4-6 weeks after the second treatment (Visit 3), the reduction from baseline in TWSTRS Total score was 20.2% (TWSTRS Total score 39.2 at baseline and 31.3 at Visit 3) [14] . In addition, all three registries had similar patient-reported outcomes as assessed by PGIC (data not shown) [14, 15] .
Registries have inherent limitations, including the lack of a control group or a prespecified statistical analysis plan, which may affect the strength of their findings.
A total of 127 patients (36.6%) discontinued treatment before the end of the study. The most common reason was patient decision (n=67). Five additional patients withdrew due to cost/reimbursement issues and 3 as a result of AEs (see Figure 1 for a complete breakout). The overall dropout rate was lower in ANCHOR-CD than in the CD-PROBE registry, 36.6% vs 52.0%, even though ANCHOR-CD had one more treatment cycle than CD-PROBE. 
CONCLUSION
Treatment of adult idiopathic CD with abobotulinumtoxinA in routine clinical practice revealed improvements in TWSTRS Total score and subscale scores, and in patient-rated measures of improvement similar to those reported in previous controlled clinical trials.
AbobotulinumtoxinA was generally well tolerated and no new safety concerns were identified. 
Highlights
 CD presents clinically with a wide range of symptom severity and comorbidities.
 AbobotulinumtoxinA efficacy in "real life" was consistent with controlled trials.
 Most common adverse events were dysphagia, muscular weakness, neck pain, and rhinorrhea, consistent with the safety profile from the pivotal placebo-controlled trials.
